NVCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Nuvectis Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$18.94+0.34 (+1.83%)
Close on Oct 19, 2026
- Market cap
- $444.64M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Community
Notes and questions about Nuvectis Pharma from other investors
No posts about NVCT yet
Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.